A version of this Priestley Medal address will be presented at the American Chemical Society Spring 2026 meeting ...

If the first CRISPR decade was marked by a mad dash to evolve, engineer, and mine the bacterial universe for more and better genome-editing enzymes, so far the second seems to be all about three words ...

Last year, a ten-month-old baby in the US was the first person in the world to have their rare genetic disease effectively cured through the use of CRISPR gene editing technology. But the rollout of ...

It acts as a sort of molecular fumigator to battle phages and plasmids. CRISPR-Cas9 has long been likened to a kind of genetic scissors, thanks to its ability to snip out any desired section of DNA ...

CRISPR Therapeutics stays a Hold as CASGEVY launch lags; watch cash burn, revenue delays, and CTX310/CTX611 catalysts for 2026. Click here to read now.

When COVID first hit, waiting days for laboratory results from an ultrasensitive polymerase chain reaction (PCR) test was commonplace. Faster tests usable by anyone, anywhere, later became widely ...

Clustered regularly interspaced short palindromic repeats (CRISPR) and CRISPR-associated (Cas) proteins are core components of fast-evolving therapeutic gene editing tools. Scientists have used CRISPR ...

In the world of biopharmaceutical innovation, 2024 will be remembered as CRISPR’s breakout year. In the spring, five patients with sickle cell disease began treatment with Casgevy, the first ...

A new Crispr-powered optical blood test detects lung cancer biomarkers at sub-attomolar levels, offering earlier molecular detection than conventional PCR or imaging.

CRISPR Therapeutics' stock decline is likely influenced by Editas Medicine's struggles, but CRISPR remains a distinct and stronger company with a promising long-term outlook. CRISPR's strategic ...